Category: Health Science
-
![vTv Therapeutics (VTVT.Q) surges 55% on type 1 diabetes drug trial]()
vTv Therapeutics (VTVT.Q) surges 55% on type 1 diabetes drug trial
“A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” stated clinical researcher Dr. John Buse.
-
![Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis]()
Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.
-
![Xphyto (XPHY.C) blowing the weed sector out of the water with true 2.0 plan]()
Xphyto (XPHY.C) blowing the weed sector out of the water with true 2.0 plan
Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from fat new high to fat new high. We’ve sat with their team several times over the past year and on each occasion have been impressed with their plans, but perhaps…
-
![Coronavirus freak-out: global markets just paid $3 trillion for a bowl of weak peacock soup]()
Coronavirus freak-out: global markets just paid $3 trillion for a bowl of weak peacock soup
A Wuhan market price list offers 112 types of wild critters including peacocks, foxes, giant salamanders, snakes, rats, porcupines and camel meat.
-
![Acceleron (XLRN.Q) gains $1.3 billion in market cap after successful phase ll trial]()
Acceleron (XLRN.Q) gains $1.3 billion in market cap after successful phase ll trial
Acceleron is finding solutions for serious and rare diseases. It has a pipeline of products moving towards commercialisation, including a co-promotion with the $152 billion Bristol-Myers Squibb (BMY.NYSE)
-
![BioTech Breakthrough: why is Greenpeace turning its back on 350,000 blind children?]()
BioTech Breakthrough: why is Greenpeace turning its back on 350,000 blind children?
With offices in 41 countries, 2.8 million members and a patriarchal structure, Greenpeace has global revenue of USD $300 million. Its most successful fundraising catalysts have been images of beautiful animals about to be slaughtered.
-
![Indignant Pharma CEO explains why the Lower Drug Costs Now Act is a terrible thing]()
Indignant Pharma CEO explains why the Lower Drug Costs Now Act is a terrible thing
“Americans spend more on prescription drugs than anyone else in the world,” states Bloomberg, “It’s true that they take a lot of pills. But what really sets the U.S. apart from most other countries is high prices.” Cancer drugs in the U.S. routinely cost $10,000 a month. The cost for old drugs has spiked, as…
-
![Yield Growth (BOSS.C) looks into 2020 crystal ball and sees a shroom boom]()
Yield Growth (BOSS.C) looks into 2020 crystal ball and sees a shroom boom
Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It has filed 13 patents to protect its extraction method and IP. Yield Growth earns revenue through multiple streams including licensing, services and product sales.
-
![Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?]()
Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion. Merck (MRK.NASDAQ) agreed to buy ArQule (ARQL.NASDAQ) for $2.7 billion, while French drug giant Sanofi (SNY.NASDAQ) agreed to purchase Synthorx (THOR.NASDAQ) for $2.5 billion. MRK has…
-
Biogen (BIIB.NASDAQ) and the brain death of big pharma
Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma execs, often paid up to 300 times more than their average employee, shot back that research and development costs were crippling and all that needed to be paid for with…
